Grifols, S.A.

GRFS· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$7.86-0.13%

2026-08-03

Financials

Valuation Metrics

Grifols, S.A.'s Market Cap is $5.35B. At end of 2025 it was $4.95B. Ranked #1340 of 3,112 in US market (top 43%), #451 of 1,445 on NASDAQ (top 31%), #78 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 29%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$5.35B	US#1,340/3,112 Sec#78/269
Revenue	$8.44B	US#651/3,112 Sec#23/269
Net Income	$471M	US#841/3,112 Sec#32/269
Total Assets	$23.61B	US#556/3,112 Sec#21/269
Net Assets	$6.42B	US#595/3,112 Sec#25/269
Value
P/E	11.35x	US#334/3,112 Sec#13/269
P/B	0.83x	US#227/3,112 Sec#9/269
PEG	0.47x	US#536/3,112 Sec#23/269
P/S	0.63x	US#371/3,112 Sec#6/269
EV/EBITDA	8.98x	US#618/3,112 Sec#24/269
FCF Yield	14.96%	US#236/3,112 Sec#11/269
Profitability
ROE	7.34%	US#1,646/3,112 Sec#61/269
ROA	2.00%	US#1,611/3,112 Sec#67/269
Op. Margin	16.88%	US#1,117/3,112 Sec#46/269
Revenue Growth	-3.24%	US#2,436/3,112 Sec#133/269
Earnings Growth	24.24%	US#849/3,112 Sec#34/269
Financial Health
Debt Ratio	224.09%	US#1,893/3,112 Sec#207/269
Total Debt	$11.37B	US#363/3,112 Sec#18/269
FCF	$800M	US#654/3,112 Sec#29/269
Cash	$825M	US#790/3,112 Sec#36/269
Current Ratio	2.47x	US#1,002/3,112 Sec#212/269
Net Debt/EBITDA	5.96x	US#2,153/3,112 Sec#86/269
Dividend
Div. Yield	2.71%	US#668/3,112 Sec#11/269
Div. Growth	12680.48%	US#5/3,112 Sec#1/269
Performance
1Y Return	-27.09%	US#2,695/3,112 Sec#223/269
1M Return	9.78%	US#542/3,112 Sec#23/269
From 52W High	-27.49%	US#2,058/3,112 Sec#151/269
1Y MDD	-35.30%	US#1,708/3,112 Sec#112/269
Trading
Volume	371,688 shares	US#2,273/3,112 Sec#222/269
Trading Value	$3M	US#2,828/3,112 Sec#234/269
Per Share
EPS	$0.64	US#1,774/3,112 Sec#59/269
BPS	$8.38	US#1,903/3,112 Sec#78/269